Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Neuroscience|August 31, 2010
Abnormal 5-HT modulation of stress behaviors in the Kv4.2 knockout mouseA Lockridge, J Su, L L YuanGlia|June 26, 2001
Electrical coupling between glial cells in the rat retinaP W Ceelen, A Lockridge, E A NewmanJournal of Rnai and Gene Silencing : an International Journal of RNA and Gene Targeting Research|October 8, 2010
Identification of small interfering RNA targeting Signal Transducer and Activator of Transcription 6: Characterisation and selection of candidates for pre-clinical developmentGareth D Healey, Shawn Zinnen, Jennifer A Lockridge, et al.Plos One|March 4, 2014
Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6Gareth D Healey, Jennifer A Lockridge, Shawn Zinnen, et al.Journal of Pharmaceutical and Biomedical Analysis|January 24, 2004
Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matricesPatricia Brown-Augsburger, Xin Min Yue, Jennifer A Lockridge, et al.Molecular Therapy. Nucleic Acids|September 18, 2017
Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B TherapyIngo Roehl, Stephan Seiffert, Celia Brikh, et al.Hepatology (Baltimore, Md.)|May 10, 2005
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replicationDavid V Morrissey, Karin Blanchard, Lucinda Shaw, et al.American Journal of Ophthalmology|July 9, 2010
RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027Peter K Kaiser, R C Andrew Symons, Syed Mahmood Shah, et al.Cancer Chemotherapy and Pharmacology|May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumorsHiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.Molecular Cancer Therapeutics|June 16, 2005
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumorsDavid E Weng, Paul A Masci, Susan F Radka, et al.Pageof 2